Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be attending the BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Tuesday, February 11, 2025, at The Cliff Lodge in Snowbird, UT.

About Personalis, Inc.

At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care from biopsy through the life of the patient. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest timepoints, enable selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Personalis is based in Fremont, California. To learn more, visit www.personalis.com and connect with us on LinkedIn and X (Twitter).

Investors: Caroline Corner investors@personalis.com 415-202-5678

Media: pr@personalis.com

Grafico Azioni Personalis (NASDAQ:PSNL)
Storico
Da Gen 2025 a Feb 2025 Clicca qui per i Grafici di Personalis
Grafico Azioni Personalis (NASDAQ:PSNL)
Storico
Da Feb 2024 a Feb 2025 Clicca qui per i Grafici di Personalis